Cairo Pharmaceuticals results, Q4 2024
Net profit, assets, equity and cash flow for Q4 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit51.04 millionEGP · +24.4% vs the same period a year earlier
Total assets1.52 billionEGP · +20.1% vs the same period a year earlier
Shareholders' equity832 millionEGP · +21.3% vs the same period a year earlier
Operating cash flow143 millionEGP · +91.8% vs the same period a year earlier
In short
- Cairo Pharmaceuticals's net profit for Q4 2024 was about 51.04 million EGP, up +24.4% from 41.04 million EGP in Q4 2023.
- Total assets at the end of Q4 2024 were about 1.52 billion EGP, and shareholders' equity about 832 million EGP.
- Operating cash flow for Q4 2024 was positive at 143 million EGP.
Key lines against the same period a year earlier
This periodQ4 2023Change
Net profit51.04 million41.04 million+24.4%
Gross profit179 million99.29 million+80.1%
Total assets1.52 billion1.26 billion+20.1%
Total liabilities683 million575 million+18.8%
Shareholders' equity832 million686 million+21.3%
Total liabilities and equity1.52 billion1.26 billion+20.1%
Operating cash flow143 million74.83 million+91.8%
Investing cash flow-70.55 million-12.51 million−463.8%
Financing cash flow-37.64 million-16.24 million−131.7%
Net change in cash35.31 million46.07 million−23.4%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy